drugset / Trial / NCT03563170
QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with advanced, unresectable, and untransplantable HCC.
Timeline
- Start
- 2018-05-25
- Primary completion
- 2019-08-23
- Completion
- 2019-08-23
Outcome
Outcome not reported
Stopped (Enrollment): “Enrollment not initiated”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aldoxorubicin | Small molecule | — | — |
| Subject | Avelumab | Monoclonal antibody | — | — |
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Cetuximab | Monoclonal antibody | — | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Subject | ETBX-011 | Vaccine | — | — |
| Subject | ETBX-051 | Vaccine | — | — |
| Subject | ETBX-061 | Vaccine | — | — |
| Subject | GI-4000 | Vaccine | — | — |
| Subject | GI-6207 | Vaccine | — | — |
| Subject | GI-6301 | Vaccine | — | — |
| Subject | Leucovorin | Small molecule | — | — |
| Subject | N-803 | Protein / enzyme biologic | — | — |
| Subject | Nab-paclitaxel | Small molecule | — | — |
| Subject | Sorafenib | Small molecule | — | Oral |
| Subject | fluorouracil | Small molecule | — | — |
| Subject | haNK | Cell therapy | — | — |